期刊文献+

组织型纤溶酶原激活因子基因真核表达质粒的构建及其体外表达研究 被引量:1

Construction and in vitro Expression of Human Tissue-type Plasminogen Activator Gene Recombinant Eukaryotic Expression Vector
下载PDF
导出
摘要 目的构建人组织型纤溶酶原激活因子(t-PA)基因的新型真核表达载体pcDNA3.1-Myc-His B(-)/t-PA,并观察其在人脐静脉内皮细胞株(hUVEC)中的表达情况。方法将t-PA基因克隆到真核表达载体pcDNA3.1-Myc-His B(-)中,经脂质体介导将pcDNA3.1-Myc-His B(-)/t-PA导入hUVEC,半定量逆转录聚合酶链反应(RT-PCR)检测t-PA基因在转染细胞内的转录水平,免疫印迹法(Western blot)检测转染细胞t-PA蛋白表达,底物发色法检测转染细胞t-PA活性。结果经双酶切鉴定和测序证实已将t-PA基因DNA片段正确插入到真核表达载体中,转基因组、空载体组、转绿色荧光蛋白组和空白对照组hUVEC t-PA mRNA相对含量分别(0.92±0.22)(、0.32±0.17)(、0.35±0.17)和(0.27±0.17),转t-PA基因组明显高于对照各组,其细胞培养上清t-PA活性分别为(48.90±8.06)、(5.44±1.09)(、5.17±0.95)和(5.01±1.03)U/106细胞.24h,转t-PA基因组t-PA活性明显高于各对照组(均P<0.01)。用抗Myc标签抗体可检测到转t-PA基因组外源性蛋白质表达,对照组则为阴性。结论成功构建pcDNA3.1-Myc-His B(-)/t-PA基因新型真核表达载体,并能在hUVEC中表达,从而为血栓性疾病的基因治疗研究奠定了基础。 Objective To construct a recombinant eukaryotic expression vector pcDNA3.1-Myc-His B(-)/t-PA including functional region of human tissue-type plasminogen activator(t-PA) gene, and investigate the expression of t-PA gene in transfected human umbilical vein endothelial cell lines (hUVEC). Methods Recombinant plasmid pcDNA3.1-Myc-His B( -)/t-PA was constructed by insertion of t-PA cDNA originated from pBS/t-PA into eukaryotic expression vector pcDNA3.1-Myc-His B (-) and transfected into hUVEC line cells mediated by lipofectamine. The transcription and expression of t-PA gene were detected by RT-PCR and Western blot respectively. The t-PA activity was measured by chromogenic substrate assay. Results t- PA cDNA was inserted into the eukaryotic expression vector correctly by using digestion identification and sequencing. In the transfected t-PA gene group, vector group, pEGFP group and blank group, the levels of t-PA mRNA were (0.92±0.22), (0. 32±0.17), (0.35±0.17) and (0.27±0.17) respectively. The content of t-PA mRNA in the transfected t-PA gene group was significantly higher than that in the control groups. The t-PA activity in the media was (48.90±8.06), (5.44±1.09), (5.17 ±0.95) and (5.01 ±1.03) U/10^6 cells/24 h respectively. The t-PA activity was increased significantly in the transfected t-PA gene group as compared with that in the control groups. The t-PA protein could be detected with anti-myc antibodies in transfected t-PA gene group. Conclusion The recombinant eukaryotic expression vector pcDNA3. 1-Myc-His B(-)/t-PA is successfully constructed and can be expressed in transfected hUVEC cell strains.
出处 《华中科技大学学报(医学版)》 CAS CSCD 北大核心 2006年第3期350-353,共4页 Acta Medicinae Universitatis Scientiae et Technologiae Huazhong
基金 国家自然科学基金资助项目(No.30571838)
关键词 组织型纤溶酶原激活因子 真核表达载体 tissue-type plasminogen activator eukaryotic expression vector
  • 相关文献

参考文献7

  • 1COLLEN D, LIJNEN H R. New thrombolytic agents and strategies[J]. Baillieres Clin Haematol, 1995,8(2) : 425-435.
  • 2COLLEN D,LIJNEN H R. Thrombolytic agents[J]. Thromb haemost, 2005,93(4) : 627-630.
  • 3GIBSON C M,CANNON C P, MURPHY S A,et al. Weight-adjusted dosing of TNK-tissue plasminogen activator and its relation to angiographic outcomes in the thrombolysis in myocardial infarction 10B trial. Tim 10B Investigators[J]. Am J Cardiol, 1999,84 (9) : 976-980.
  • 4FREY J L. Recombinant tissue plasminogen activator (rtPA)for stroke. The perspective at 8 years[J]. Neurologist, 2005,11(2):123-133.
  • 5WAUGH J M, KATTASH M, LI J, et al. Gene therapy to promote thromhoresistance :local over expression of tissue plasminogen activator to prevent arterial thrombosis in an in vivo rabbit model[J]. Proc Natc Acad Sci USA,1999,96(3):1065-1070.
  • 6DICHEK D A, NEVILLE R F, Zwiebel J A, et al. Seeding of introvascular stents with genetically engineered endothelial cells[J]. Circulation, 1989, 80(5) : 1347-1353.
  • 7ETON D, YU H,WANG Y,et al. Endograft technology:a delivery vehicle for intravascular gene therapy[J]. Vasc Surg,2004,39(5):1066-1073.

同被引文献11

  • 1宦梦蕾,罗晓星,孟静茹,衡亮.脂质体包裹的反义寡核苷酸逆转耐甲氧西林金黄色葡萄球菌耐药性的研究[J].中国临床药理学与治疗学,2006,11(9):983-986. 被引量:2
  • 2祖育昆,张凯伦,蒋雄刚.交联明胶材料制备及细胞毒性的实验研究[J].微循环学杂志,2007,17(3):10-12. 被引量:1
  • 3Kahn JH,Viereck J,Kase C,et al.The use of intravenous recombinant tissue plasminogen activator in acute ischemic stroke.J Emerg Med,2005,29(3):273-277.
  • 4Mchay MJ,Gaballa MA.Gene transfer therapy in vascular disease.J Cardiovasc Drug Rev,2001,19(3):245-252.
  • 5Iwatate M,Gu Y,Dieterle T,et al.In vivo high-efficiency transcoronary gene delivery and Cre-LoxP gene switching in the adult mouse heart.Gene Ther,2003,10(21):1 814-1 820.
  • 6Weadock KS,Olson RM,Sliver FH.Evaluation of collagen crosslinking techniques.Med Dev Art Org,1983-1984,11(4):295-328.
  • 7萨姆布鲁克J,弗里奇EF,曼尼阿蒂斯T,著.黄培堂,译.分子克隆实验指南.北京:科学出版社,1993:956.
  • 8Yamamoto M,Ikada Y,Tabata Y.Controlled release of growth factors based on biodegradation of gelatin hydrogel.J Bioma Sci Polym,2001,12(7):77-88.
  • 9Yasunori F,Kazunori I,Kazuhiro M,et al.Controlled release of plasmid DNA from cationized gelatin hydrogels based on hydrogel degradation.J Con Rel,2002,80(5):333-343.
  • 10Kabanov AV.DNA complexes with polycations for the delivery of genetic material into cells.J Bioconjug Chem,1995,6(3):7-20.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部